BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in therapeutic, vaccine and diagnostic COVID-19 programs, including GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients....
BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
BC Innovations | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Extra | Nov 13, 2018
Company News

Management tracks: Anchiano, ContraFect

Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc. (OTCQB:ARPO). Anchiano also named Robert Connelly a director. He was a venture partner at Flagship Pioneering and...
BC Week In Review | Jul 13, 2018
Clinical News

Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving the complete clearance rate of baseline anogenital warts (condyloma) by week 16 vs. placebo in a Phase II trial...
BC Week In Review | Feb 16, 2018
Clinical News

Vaxart's VXA-A1.1 vaccine meets in Phase II influenza trial

In October, Vaxart Inc. (San Francisco, Calif.) reported top-line data from a Phase II trial in about 180 subjects showing that oral H1N1 influenza vaccine (VXA-A1.1) met the primary endpoint of reducing the occurrence of...
BC Week In Review | Mar 17, 2017
Clinical News

VXA-G1.1-NN: Ph I data

A double-blind, placebo-controlled, U.S. Phase I trial in 66 healthy volunteers showed that single doses of 1×10 10 and 1×10 11 IU oral VXA-G1.1-NN both met the primary endpoint of safety. Specifically, both doses of...
BC Innovations | Sep 15, 2016
Targets & Mechanisms

Bon voyage!

For over 40 years, researchers have tried to grow norovirus in the lab without success. A Baylor College of Medicine group has cracked the problem by using 3-D cultures to discover exactly what cell type...
BC Week In Review | Jul 11, 2016
Clinical News

Oral respiratory syncytial virus: Phase I started

Vaxart began a double-blind, placebo-controlled Phase I trial to evaluate an oral RSV vaccine in 66 healthy volunteers. Vaxart Inc. , San Francisco, Calif.   Product: Oral respiratory syncytial virus (RSV) vaccine   Business: Infectious  ...
Items per page:
1 - 10 of 38
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in therapeutic, vaccine and diagnostic COVID-19 programs, including GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients....
BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
BC Innovations | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Extra | Nov 13, 2018
Company News

Management tracks: Anchiano, ContraFect

Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc. (OTCQB:ARPO). Anchiano also named Robert Connelly a director. He was a venture partner at Flagship Pioneering and...
BC Week In Review | Jul 13, 2018
Clinical News

Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving the complete clearance rate of baseline anogenital warts (condyloma) by week 16 vs. placebo in a Phase II trial...
BC Week In Review | Feb 16, 2018
Clinical News

Vaxart's VXA-A1.1 vaccine meets in Phase II influenza trial

In October, Vaxart Inc. (San Francisco, Calif.) reported top-line data from a Phase II trial in about 180 subjects showing that oral H1N1 influenza vaccine (VXA-A1.1) met the primary endpoint of reducing the occurrence of...
BC Week In Review | Mar 17, 2017
Clinical News

VXA-G1.1-NN: Ph I data

A double-blind, placebo-controlled, U.S. Phase I trial in 66 healthy volunteers showed that single doses of 1×10 10 and 1×10 11 IU oral VXA-G1.1-NN both met the primary endpoint of safety. Specifically, both doses of...
BC Innovations | Sep 15, 2016
Targets & Mechanisms

Bon voyage!

For over 40 years, researchers have tried to grow norovirus in the lab without success. A Baylor College of Medicine group has cracked the problem by using 3-D cultures to discover exactly what cell type...
BC Week In Review | Jul 11, 2016
Clinical News

Oral respiratory syncytial virus: Phase I started

Vaxart began a double-blind, placebo-controlled Phase I trial to evaluate an oral RSV vaccine in 66 healthy volunteers. Vaxart Inc. , San Francisco, Calif.   Product: Oral respiratory syncytial virus (RSV) vaccine   Business: Infectious  ...
Items per page:
1 - 10 of 38